Objective: To evaluate FOXA1 as a prognostic/predictive factor for tumor recurrence in invasive breast carcinoma, examine the correlation between FOXA1 expression in luminal subtype A and the absence of recurrence, and assess the value of FOXA1 levels as a potential modulator of chemotherapy response. Study Design: We identified 234 patients diagnosed with non-special type invasive mammary carcinoma who received no neoadjuvant treatment and were followed up for a minimum of 7 years. Tissue microarrays were constructed for immunohistochemical examination (ER, PR, p53, Ki-67, HER2, and FOXA1). Results: Univariate analysis revealed an inverse correlation between tumor recurrence and FOXA1 expression (p=0.005; Exp(B) 0.404). The findings highlighted the statistically significant linear correlation of luminal A phenotype (p=0.086), high FOXA1 expression (p= 0.009), and absence of lymph node metastasis (p=0.033) with a reduction in the risk of recurrence (p=0.035, Exp(B):0.94) by almost 6%. Conclusion: The present study pointed to a direct correlation between FOXA1 expression in breast cancer and a reduced risk of recurrence. FOXA1 expression might argue against the use of adjuvant chemotherapy in ER+/lymph node-negative patients. Our study also suggests that routinely detected FOXA1 might be used in the luminal A subtype of breast cancer, in particular those patients in whom neoadjuvant chemotherapy is in consideration. © Science Printers and Publishers, Inc.